

# George T Grossberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3110431/publications.pdf>

Version: 2024-02-01

53  
papers

3,119  
citations

218677

26  
h-index

197818

49  
g-index

57  
all docs

57  
docs citations

57  
times ranked

4465  
citing authors

#	ARTICLE	IF	CITATIONS
1	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1917-1933.	7.6	1,008
2	Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease: Current Therapeutic Research, 2003, 64, 216-235.	1.2	232
3	Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 731-739.	2.5	222
4	The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer's Disease Taking Cholinesterase Inhibitors. <i>CNS Drugs</i> , 2013, 27, 469-478.	5.9	128
5	An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 171-178.	2.4	98
6	An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 147-157.	2.4	97
7	The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease. <i>Drugs and Aging</i> , 2015, 32, 537-547.	2.7	96
8	The role of 5-HT <sub>6</sub> -receptor antagonists in Alzheimer's disease: an update. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 523-533.	4.1	84
9	A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3267-3279.	4.3	77
10	Combination Therapy for Alzheimer's Disease. <i>Drugs and Aging</i> , 2011, 28, 539-546.	2.7	75
11	Pharmacology of Acetylcholinesterase Inhibitors and N-methyl-D-aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 8S-16S.	2.0	69
12	Behavioral and Psychological Symptoms of Dementia as a Risk Factor for Nursing Home Placement. <i>International Psychogeriatrics</i> , 2000, 12, 59-62.	1.0	68
13	Management of Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, M331-M353.	3.6	65
14	A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24h Versus 4.6 mg/24h in Severe Alzheimer's Dementia. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 745-752.	3.9	63
15	Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 164-172.	1.5	50
16	The ABC of Alzheimer's Disease: Behavioral Symptoms and Their Treatment. <i>International Psychogeriatrics</i> , 2002, 14, 27-49.	1.0	49
17	Recent Progress in the Pharmacotherapy of Alzheimer's Disease. <i>Drugs and Aging</i> , 2017, 34, 811-820.	2.7	46
18	Evaluation of rivastigmine in Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2021, 11, 35-48.	2.2	45

#	ARTICLE	IF	CITATIONS
19	An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2018, 19, 1711-1717.	1.8	41
20	Safety and Tolerability of the Rivastigmine Patch. Alzheimer Disease and Associated Disorders, 2009, 23, 158-164.	1.3	39
21	Cognitive Deficit Reversal as Shown by Changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) Examination Scores 7.5 Years Later. Journal of the American Medical Directors Association, 2014, 15, 687.e5-687.e10.	2.5	39
22	Amyloid and Tau Biomarkers in Subjective Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 1-8.	2.6	39
23	Drug-Induced Seizures in the Elderly. Drugs and Aging, 1995, 7, 38-48.	2.7	36
24	Rivastigmine for Alzheimer's disease. Expert Review of Neurotherapeutics, 2005, 5, 563-580.	2.8	35
25	Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Expert Opinion on Pharmacotherapy, 2001, 2, 653-666.	1.8	31
26	The Saint Louis University Mental Status Examination Is Better than the Mini-Mental State Examination to Determine the Cognitive Impairment in Turkish Elderly People. Journal of the American Medical Directors Association, 2016, 17, 370.e11-370.e15.	2.5	27
27	Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias. Drugs and Aging, 2019, 36, 719-731.	2.7	27
28	Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. Current Medical Research and Opinion, 2005, 21, 1631-1639.	1.9	21
29	Dietary Interventions to Prevent or Delay Alzheimer's Disease: What the Evidence Shows. Current Nutrition Reports, 2020, 9, 210-225.	4.3	20
30	Rivastigmine From Capsules to Patch. primary care companion for CNS disorders, The, 2014, 16, .	0.6	20
31	AVP-786 as a promising treatment option for Alzheimer's Disease including agitation. Expert Opinion on Pharmacotherapy, 2021, 22, 783-795.	1.8	19
32	Rational deprescribing in the elderly. Annals of Clinical Psychiatry, 2019, 31, 144-152.	0.6	19
33	Brain Games to Slow Cognitive Decline in Alzheimer's Disease. Journal of the American Medical Directors Association, 2014, 15, 536-537.	2.5	16
34	Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease. Expert Opinion on Emerging Drugs, 2017, 22, 101-105.	2.4	16
35	Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers. Journal of Geriatric Psychiatry and Neurology, 2021, 34, 274-279.	2.3	16
36	Deciphering Alzheimer's disease: predicting new therapeutic strategies via improved understanding of biology and pathogenesis. Expert Opinion on Therapeutic Targets, 2020, 24, 859-868.	3.4	11

#	ARTICLE	IF	CITATIONS
37	An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2020, 21, 619-627.	1.8	11
38	Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents. Current Alzheimer Research, 2018, 15, 964-974.	1.4	9
39	Pharmacotherapy for Frontotemporal Dementia. CNS Drugs, 2021, 35, 425-438.	5.9	9
40	Eating disturbances in the elderly: A geriatric-psychiatric perspective. Nutrition and Healthy Aging, 2019, 5, 185-198.	1.1	7
41	Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications. CNS Drugs, 2019, 33, 17-29.	5.9	7
42	Testing the Cognitive Reserve Index Questionnaire in an Alzheimer's Disease Population. Journal of Alzheimer's Disease Reports, 2020, 4, 513-524.	2.2	7
43	Impact of agitation in long-term care residents with dementia in the United States. International Journal of Geriatric Psychiatry, 2021, 36, 1959-1969.	2.7	6
44	P1-370: EFFICACY AND TOLERABILITY OF MEMANTINE EXTENDED RELEASE ADDED TO STABLE DONEPEZIL REGIMEN IN INDIVIDUALS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE: SUBSET ANALYSIS OF A RANDOMIZED CLINICAL TRIAL. , 2014, 10, P450-P450.		4
45	Comparison of the Impact of the Mediterranean Diet, Anti-Inflammatory Diet, Seventh-Day Adventist Diet, and Ketogenic Diet Relative to Cognition and Cognitive Decline. Current Nutrition Reports, 2022, 11, 161-171.	4.3	4
46	Orexigenic agents in geriatric clinical practice. Aging Health, 2013, 9, 49-65.	0.3	3
47	The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Current Geriatrics Reports, 2015, 4, 301-311.	1.1	2
48	Diagnostic Accuracy of the SLU AMSAD Scale for Depression in Older Adults Without Dementia. Journal of the American Medical Directors Association, 2020, 21, 665-668.	2.5	1
49	Alcohol, Drugs, and Baby Boomers. Clinics in Geriatric Medicine, 2022, 38, xiii-xiv.	2.6	1
50	Geriatric psychiatry—an emerging specialty. Missouri Medicine, 2010, 107, 401-5.	0.3	1
51	Pharmacotherapy for Alzheimer's disease: what's new on the horizon?. Expert Opinion on Pharmacotherapy, 0, , 1-19.	1.8	1
52	P1-173: IDEOMOTOR LIMB APRAXIA IN INDIVIDUALS WITH ALZHEIMER'S DISEASE DEMENTIA (ILIAD). , 2014, 10, P363-P363.		0
53	P1-023: EFFICACY AND SAFETY OF OVER-THE-COUNTER MEMORY-ENHANCING SUPPLEMENTS: WHAT THE EVIDENCE SHOWS. , 2014, 10, P312-P312.		0